TY - JOUR
T1 - Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma
AU - Matsuo, Koji
AU - Wong, Kwong Kwok
AU - Fotopoulou, Christina
AU - Blake, Erin A.
AU - Robertson, Sharon E.
AU - Pejovic, Tanja
AU - Frimer, Marina
AU - Pardeshi, Vishakha
AU - Hu, Wei
AU - Choi, Jong Sun
AU - Sun, Charlotte C.
AU - Richmond, Abby M.
AU - Marcus, Jenna Z.
AU - Hilliard, Maren A.M.
AU - Mostofizadeh, Sayedamin
AU - Mhawech-Fauceglia, Paulette
AU - Abdulfatah, Eman
AU - Post, Miriam D.
AU - Saglam, Ozlen
AU - Shahzad, Mian M.K.
AU - Karabakhtsian, Rouzan G.
AU - Ali-Fehmi, Rouba
AU - Gabra, Hani
AU - Roman, Lynda D.
AU - Sood, Anil K.
AU - Gershenson, David M.
N1 - Funding Information:
This work was supported by Ensign Endowment for Gynecologic
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background and Objectives: To examine association of lympho-vascular space invasion (LVSI) with clinico-pathological factors and to evaluate survival of women with low-grade serous ovarian carcinoma containing areas of LVSI. Methods: This is a multicenter retrospective study examining consecutive cases of surgically treated stage I-IV low-grade serous ovarian carcinoma (n = 178). Archived histopathology slides for the ovarian tumors were reviewed, and LVSI was scored as present or absent. LVSI status was correlated to clinico-pathological findings and survival outcome. Results: LVSI was seen in 79 cases (44.4%, 95% confidence interval [CI] 37.1-51.7). LVSI was associated with increased risk of omental metastasis (87.0% vs 64.9%, odds ratio [OR] 3.62, P = 0.001), high pelvic lymph node ratio (median 12.9% vs 0%, P = 0.012), and malignant ascites (49.3% vs 32.6%, OR 2.01, P = 0.035). On multivariable analysis, controlling for age, stage, and cytoreductive status, presence of LVSI in the ovarian tumor remained an independent predictor for decreased progression-free survival (5-year rates 21.0% vs 35.7%, adjusted-hazard ratio 1.57, 95%CI 1.06-2.34, P = 0.026). LVSI was significantly associated with increased risk of recurrence in lymph nodes (OR 2.62, 95%CI 1.08-6.35, P = 0.047). Conclusion: LVSI in the ovarian tumor is associated with adverse clinico-pathological characteristics and decreased progression-free survival in women with low-grade serous ovarian carcinoma.
AB - Background and Objectives: To examine association of lympho-vascular space invasion (LVSI) with clinico-pathological factors and to evaluate survival of women with low-grade serous ovarian carcinoma containing areas of LVSI. Methods: This is a multicenter retrospective study examining consecutive cases of surgically treated stage I-IV low-grade serous ovarian carcinoma (n = 178). Archived histopathology slides for the ovarian tumors were reviewed, and LVSI was scored as present or absent. LVSI status was correlated to clinico-pathological findings and survival outcome. Results: LVSI was seen in 79 cases (44.4%, 95% confidence interval [CI] 37.1-51.7). LVSI was associated with increased risk of omental metastasis (87.0% vs 64.9%, odds ratio [OR] 3.62, P = 0.001), high pelvic lymph node ratio (median 12.9% vs 0%, P = 0.012), and malignant ascites (49.3% vs 32.6%, OR 2.01, P = 0.035). On multivariable analysis, controlling for age, stage, and cytoreductive status, presence of LVSI in the ovarian tumor remained an independent predictor for decreased progression-free survival (5-year rates 21.0% vs 35.7%, adjusted-hazard ratio 1.57, 95%CI 1.06-2.34, P = 0.026). LVSI was significantly associated with increased risk of recurrence in lymph nodes (OR 2.62, 95%CI 1.08-6.35, P = 0.047). Conclusion: LVSI in the ovarian tumor is associated with adverse clinico-pathological characteristics and decreased progression-free survival in women with low-grade serous ovarian carcinoma.
KW - low-grade serous
KW - lymphovascular space invasion
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85042512764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042512764&partnerID=8YFLogxK
U2 - 10.1002/jso.24801
DO - 10.1002/jso.24801
M3 - Article
C2 - 28787528
AN - SCOPUS:85042512764
SN - 0022-4790
VL - 117
SP - 236
EP - 244
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 2
ER -
